FOLD up +0.89% percent Today $FOLD High is at 7.05 and the Low 6.64 with current volume of 5,162,652.
Recent News posted below.
Amicus Therapeutics FOLD other info.
http://investorshangout.com/Amicus-Therapeuti...OLD-54154/
FOLD Amicus Therapeutics Recent Headline News
Amicus prices stock offering
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:13AM CST
FOLD: 6.48 (-0.27)
Amicus Therapeutics prices offering of common stock at USD6.50 per share
M2 - Wed Nov 19, 5:53AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) revealed on Tuesday that it has priced an offering of 13,850,000 shares of its common stock at USD6.50 per share.
FOLD: 6.48 (-0.27)
Amicus Therapeutics Prices Underwritten Offering of Common Stock
GlobeNewswire - Tue Nov 18, 6:15PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 13,850,000 shares of its common stock at $6.50 per share. The gross proceeds from the offering to Amicus are expected to be $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,077,500 shares of its common stock. The offering is expected to close on November 24, 2014, subject to customary closing conditions.
JPM: 60.63 (+0.10), FOLD: 6.48 (-0.27)
Nokia and Urban Outfitters are big market movers
AP - Tue Nov 18, 3:50PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.89 (-0.34), HAS: 56.22 (+0.10), HD: 96.65 (+0.67), MDT: 71.90 (-0.57), HAL: 48.47 (-0.07), CSIQ: 26.98 (-0.38), NOK: 7.76 (-0.17), URBN: 29.38 (+0.59), AGN: 212.51 (-0.86), DNR: 9.80 (-0.21), MITL: 9.93 (-0.03), AAPL: 114.85 (-0.62), FOLD: 6.48 (-0.27), BHI: 63.54 (-0.01)
Amicus' Migalastat Should Have Smooth Sailing To FDA And European Approval For Fabry Disease
Clinically Sound Investor - at Seeking Alpha - Tue Nov 18, 8:47AM CST
FOLD: 6.48 (-0.27)
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:21AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 56.00 (+0.34), AMAG: 35.58 (+0.24), AFFX: 8.93 (-0.65), FOLD: 6.48 (-0.27)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 29.38 (+0.59), DHX: 10.92 (-0.36), ACT: 265.85 (-3.75), OME: 11.54 (-0.91), CLVS: 49.25 (-4.53), AVB: 157.25 (-1.00), PF: 32.63 (+0.15), RMTI: 9.97 (-0.31), GLW: 20.43 (+0.01), FOLD: 6.48 (-0.27)
Market News: Amicus Therapeutics, Urban Outfitters, Ford
at The Street - Mon Nov 17, 4:08PM CST
Chad Morganlander of Stifel Nicolaus commented that the overriding concern is that global growth is continuing to decelerateThe stock markets in the United States moved slightly with the Dow Jones Ind...
URBN: 29.38 (+0.59), F: 15.46 (-0.04), FOLD: 6.48 (-0.27)
Amicus Therapeutics Earnings Hindsight: Down 3.2% in Last 11 Days (FOLD)
Comtex SmarTrend(R) - Mon Nov 17, 3:01PM CST
A week ago on November 6th, 2014 Amicus Therapeutics (NASDAQ:FOLD) reported earnings and analysts, on average, expected a loss of $0.21 on sales of $500.0 thousand. The company actually reported a loss of $0.23 per share on sales of $293.0 thousand, missing EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Amicus Therapeutics have fallen from $5.88 to $5.69, representing a loss of 3.2% in the past 11 days.
FOLD: 6.48 (-0.27)
Amicus Therapeutics Announces Public Offering of Common Stock
GlobeNewswire - Mon Nov 17, 3:00PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $75 million underwritten public offering of its common stock. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
JPM: 60.62 (+0.09), FOLD: 6.48 (-0.27)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.11 (-0.32), ANV: 1.68 (-0.36), BONE: 3.05 (-0.11), WLH: 19.13 (-0.03), CLDX: 19.15 (+1.43), ENZY: 8.19 (-0.06), TGEN: 5.87 (-0.35), CHOP: 2.10 (-0.03), MSBF: 9.90 (-0.01), NVGN: 1.70 (-0.10), DWA: 22.65 (+0.17), WHX: 2.26 (-0.08), VYFC: 19.73 (-0.02), VGGL: 3.20 (-0.21), SNSS: 2.13 (+0.06), DNR: 9.80 (-0.21), MOBI: 5.57 (-0.32), VPCO: 1.56 (-0.03), FOLD: 6.48 (-0.27), ATEA: 1.40 (-0.06)
Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results
at The Street - Mon Nov 17, 10:27AM CST
Shares of Amicus Therapeutics (FOLD) rose in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.
FOLD: 6.48 (-0.27)
Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
at The Street - Mon Nov 17, 9:02AM CST
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 6.48 (-0.27)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.11 (-0.32), INO: 9.44 (-0.42), CLDX: 19.15 (+1.43), HAL: 48.48 (-0.06), ROX: 1.66 (-0.12), SNSS: 2.13 (+0.06), DNR: 9.80 (-0.21), DWA: 22.65 (+0.17), GSAT: 2.66 (+0.11), CMGE: 25.19 (-0.97), FOLD: 6.48 (-0.27), BHI: 63.54 (-0.01)
Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST
SHPG: 208.28 (-1.72), SNY: 48.26 (-0.10), FOLD: 6.48 (-0.27)
Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 208.28 (-1.72), SNY: 48.26 (-0.10), FOLD: 6.47 (-0.28)
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
GlobeNewswire - Sat Nov 15, 9:00AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat"
for Fabry disease. In a poster at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. A slide presentation featuring these data is also available at http://ir.amicustherapeutics.com/events.cfm.
FOLD: 6.47 (-0.28)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 3.90 (-0.09), OPK: 8.18 (-0.05), PTCT: 39.65 (-0.41), ATHX: 1.43 (+0.04), FOLD: 6.47 (-0.28)
Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 8:50AM CST
FOLD: 6.47 (-0.28)
Amicus Therapeutics posts 3Q loss
Automated Insights - Thu Nov 06, 5:30PM CST
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $17.1 million, or 22 cents per share, in its third quarter.
FOLD: 6.47 (-0.28)
Recent News posted below.
Amicus Therapeutics FOLD other info.
http://investorshangout.com/Amicus-Therapeuti...OLD-54154/
FOLD Amicus Therapeutics Recent Headline News
Amicus prices stock offering
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 6:13AM CST
FOLD: 6.48 (-0.27)
Amicus Therapeutics prices offering of common stock at USD6.50 per share
M2 - Wed Nov 19, 5:53AM CST
Biopharmaceutical company Amicus Therapeutics (NasdaqGM:FOLD) revealed on Tuesday that it has priced an offering of 13,850,000 shares of its common stock at USD6.50 per share.
FOLD: 6.48 (-0.27)
Amicus Therapeutics Prices Underwritten Offering of Common Stock
GlobeNewswire - Tue Nov 18, 6:15PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 13,850,000 shares of its common stock at $6.50 per share. The gross proceeds from the offering to Amicus are expected to be $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,077,500 shares of its common stock. The offering is expected to close on November 24, 2014, subject to customary closing conditions.
JPM: 60.63 (+0.10), FOLD: 6.48 (-0.27)
Nokia and Urban Outfitters are big market movers
AP - Tue Nov 18, 3:50PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.89 (-0.34), HAS: 56.22 (+0.10), HD: 96.65 (+0.67), MDT: 71.90 (-0.57), HAL: 48.47 (-0.07), CSIQ: 26.98 (-0.38), NOK: 7.76 (-0.17), URBN: 29.38 (+0.59), AGN: 212.51 (-0.86), DNR: 9.80 (-0.21), MITL: 9.93 (-0.03), AAPL: 114.85 (-0.62), FOLD: 6.48 (-0.27), BHI: 63.54 (-0.01)
Amicus' Migalastat Should Have Smooth Sailing To FDA And European Approval For Fabry Disease
Clinically Sound Investor - at Seeking Alpha - Tue Nov 18, 8:47AM CST
FOLD: 6.48 (-0.27)
Amicus Therapeutics, Inc. (FOLD) in Focus: Stock Soars 17.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:21AM CST
Amicus Therapeutics, Inc. (FOLD) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 56.00 (+0.34), AMAG: 35.58 (+0.24), AFFX: 8.93 (-0.65), FOLD: 6.48 (-0.27)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST
URBN: 29.38 (+0.59), DHX: 10.92 (-0.36), ACT: 265.85 (-3.75), OME: 11.54 (-0.91), CLVS: 49.25 (-4.53), AVB: 157.25 (-1.00), PF: 32.63 (+0.15), RMTI: 9.97 (-0.31), GLW: 20.43 (+0.01), FOLD: 6.48 (-0.27)
Market News: Amicus Therapeutics, Urban Outfitters, Ford
at The Street - Mon Nov 17, 4:08PM CST
Chad Morganlander of Stifel Nicolaus commented that the overriding concern is that global growth is continuing to decelerateThe stock markets in the United States moved slightly with the Dow Jones Ind...
URBN: 29.38 (+0.59), F: 15.46 (-0.04), FOLD: 6.48 (-0.27)
Amicus Therapeutics Earnings Hindsight: Down 3.2% in Last 11 Days (FOLD)
Comtex SmarTrend(R) - Mon Nov 17, 3:01PM CST
A week ago on November 6th, 2014 Amicus Therapeutics (NASDAQ:FOLD) reported earnings and analysts, on average, expected a loss of $0.21 on sales of $500.0 thousand. The company actually reported a loss of $0.23 per share on sales of $293.0 thousand, missing EPS estimates by $0.02 and matching revenue estimates. Since the company's report, shares of Amicus Therapeutics have fallen from $5.88 to $5.69, representing a loss of 3.2% in the past 11 days.
FOLD: 6.48 (-0.27)
Amicus Therapeutics Announces Public Offering of Common Stock
GlobeNewswire - Mon Nov 17, 3:00PM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $75 million underwritten public offering of its common stock. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
JPM: 60.62 (+0.09), FOLD: 6.48 (-0.27)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:47AM CST
CADC: 5.11 (-0.32), ANV: 1.68 (-0.36), BONE: 3.05 (-0.11), WLH: 19.13 (-0.03), CLDX: 19.15 (+1.43), ENZY: 8.19 (-0.06), TGEN: 5.87 (-0.35), CHOP: 2.10 (-0.03), MSBF: 9.90 (-0.01), NVGN: 1.70 (-0.10), DWA: 22.65 (+0.17), WHX: 2.26 (-0.08), VYFC: 19.73 (-0.02), VGGL: 3.20 (-0.21), SNSS: 2.13 (+0.06), DNR: 9.80 (-0.21), MOBI: 5.57 (-0.32), VPCO: 1.56 (-0.03), FOLD: 6.48 (-0.27), ATEA: 1.40 (-0.06)
Amicus Therapeutics (FOLD) Stock Surges Following Fabry Treatment Pill Results
at The Street - Mon Nov 17, 10:27AM CST
Shares of Amicus Therapeutics (FOLD) rose in morning trading Monday after the company announced positive results of its experimental pill migalastat in patients with Fabry disease.
FOLD: 6.48 (-0.27)
Amicus Therapeutics (FOLD) Strong On High Relative Volume Today
at The Street - Mon Nov 17, 9:02AM CST
Trade-Ideas LLC identified Amicus Therapeutics (FOLD) as a strong on high relative volume candidate
FOLD: 6.48 (-0.27)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:15AM CST
CADC: 5.11 (-0.32), INO: 9.44 (-0.42), CLDX: 19.15 (+1.43), HAL: 48.48 (-0.06), ROX: 1.66 (-0.12), SNSS: 2.13 (+0.06), DNR: 9.80 (-0.21), DWA: 22.65 (+0.17), GSAT: 2.66 (+0.11), CMGE: 25.19 (-0.97), FOLD: 6.48 (-0.27), BHI: 63.54 (-0.01)
Amicus Therapeutics' Fabry disease drug candidate improves cardiac health marker
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 6:31AM CST
SHPG: 208.28 (-1.72), SNY: 48.26 (-0.10), FOLD: 6.48 (-0.27)
Amicus Drug Improves Marker of Heart Health in Fabry Patients
at The Street - Sat Nov 15, 9:01AM CST
The new migalastat data compliment earlier esults from successful phase III study announced in August by Amicus.
SHPG: 208.28 (-1.72), SNY: 48.26 (-0.10), FOLD: 6.47 (-0.28)
Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
GlobeNewswire - Sat Nov 15, 9:00AM CST
Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl ("migalastat"
for Fabry disease. In a poster at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. A slide presentation featuring these data is also available at http://ir.amicustherapeutics.com/events.cfm. FOLD: 6.47 (-0.28)
Global Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Therapeutics Pipeline Review H2 2014 - Analysis of 9 Companies & 12 Drug Profiles
M2 - Tue Nov 11, 5:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/hphx7p/mucopolysaccharido) has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Athersys, Inc. - OPKO Health, Inc. - Amicus Therapeutics, Inc. - ReGenX Biosciences, LLC - AngioChem Inc. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - biOasis Technologies Inc. - ArmaGen Technologies, Inc. Drug Profiles - ataluren - FT-1050 - MultiStem - AGT-181 - Gene Therapy to Activate Iduronidase for Hurler Syndrome - Oligonucleotide for Mucopolysaccharidosis I - (laronidase Chaperone) - Recombinant Enzyme for Hurler Syndrome - Stem Cell Therapy for Type1 Mucopolysaccharidosis - Cell Therapy for Mucopolysaccharidosis I - Cell Therapy to Activate Iduronidase for Hurler Syndrome - Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I For more information visit http://www.researchandmarkets.com/research/hp...saccharido
FATE: 3.90 (-0.09), OPK: 8.18 (-0.05), PTCT: 39.65 (-0.41), ATHX: 1.43 (+0.04), FOLD: 6.47 (-0.28)
Amicus Therapeutics' (FOLD) CEO John Crowley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 09, 8:50AM CST
FOLD: 6.47 (-0.28)
Amicus Therapeutics posts 3Q loss
Automated Insights - Thu Nov 06, 5:30PM CST
CRANBURY, N.J. (AP) _ Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $17.1 million, or 22 cents per share, in its third quarter.
FOLD: 6.47 (-0.28)
